Literature DB >> 316434

Meningitis due to Haemophilus influenzae type e biotype 4.

H Shishido, K Matsumoto.   

Abstract

Haemophilus influenzae type e biotype 4 was isolated from the cerebrospinal fluid of a 16-month-old child with meningitis. This is the first isolation, from a case of meningitis, of this organism that has been biotyped.

Entities:  

Mesh:

Year:  1979        PMID: 316434      PMCID: PMC273295          DOI: 10.1128/jcm.10.6.926-927.1979

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Incidence and type distribution of capsulated H. influenzae strains.

Authors:  B DAWSON; K ZINNEMANN
Journal:  Br Med J       Date:  1952-04-05

2.  Bacteremia associated with Haemophilus influenzae type e biotype 4.

Authors:  T H Cawthern; R V Marraro; F K McCleskey
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

3.  Type b haemophilus influenzae infections in adults.

Authors:  L Weinstein
Journal:  N Engl J Med       Date:  1970-01-22       Impact factor: 91.245

4.  Meningitis and bacteremia due to Haemophilus influenzae: occurrence and mortality at Boston City Hospital in 12 selected years, 1935-1972.

Authors:  J E McGowan; J O Klein; L Bratton; M W Barnes; M Finland
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

5.  Meningitis due to Haemophilus influenzae type e.

Authors:  L L Buck; G W Douglas
Journal:  J Clin Microbiol       Date:  1976-10       Impact factor: 5.948

6.  A taxonomic study of the genus Haemophilus, with the proposal of a new species.

Authors:  M Kilian
Journal:  J Gen Microbiol       Date:  1976-03

7.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

8.  Serological studies on Haemophilus influenzae and related species. 2. Examination of the type specific antigens of H. influenzae by means of the capsular swelling method.

Authors:  T OMLAND
Journal:  Acta Pathol Microbiol Scand       Date:  1963

9.  Iodometric detection of Haemophilus influenzae beta-lactamase: rapid presumptive test for ampicillin resistance.

Authors:  B W Catlin
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

10.  Meningitis due to an unusual type of Haemophilus influenzae.

Authors:  F J Bone
Journal:  Scott Med J       Date:  1975-01       Impact factor: 0.729

  10 in total
  6 in total

1.  Comparative virulence of Haemophilus influenzae with a type b or type d capsule.

Authors:  M Roberts; T L Stull; A L Smith
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

2.  Distribution and relationship to serotype of Haemophilus influenzae biotypes isolated from upper respiratory tracts of children and adults in Papua New Guinea.

Authors:  M Gratten; T Lupiwa; J Montgomery; G Gerega
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

3.  Lethal meningoencephalitis and septicemia caused by Haemophilus influenzae type f in an adult with multiple myeloma.

Authors:  W C Wagener; R L Myerowitz; G M Dulabon
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

4.  Clinical evaluation of piperacillin with observations on penetrability into cerebrospinal fluid.

Authors:  G M Dickinson; D G Droller; R L Greenman; T A Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

5.  In vitro activities of piperacillin against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  Yoshiro Morikawa; Miyoshi Kitazato; Junichi Mitsuyama; Shingo Mizunaga; Shinzaburo Minami; Yasuo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 6.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.